◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW HIGH

PPAP

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

PPAP is the first CAE compound and a historical-mechanistic milestone, but its successor BPAP is ~130× more potent in vivo (full antagonism of tetrabenazine depression at 0.05 mg/kg vs PPAP's 2.5 mg/kg), enhances serotonin in addition to catecholamines, and is the actively-researched compound in this family. For Dylan-archetype the rational move at this CAE-class slot is BPAP if the watch-list moves to active, OR low-dose selegiline (which has 40+ years of human data and Rx access) if MAO-B inhibition is also wanted. PPAP has zero unique value vs BPAP and zero human RCTs. Would re-evaluate ONLY if BPAP sourcing collapses AND a human PPAP trial emerges — not expected.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    PPAP has zero unique value vs the alternatives. If the goal is MAO-B-preserving DA tone, low-dose selegiline (1-2.5 mg) has 40+ years of human safety data and an Rx path. If the goal is pure CAE without MAO inhibition, BPAP is ~130× more potent in vivo, adds serotonin enhancement, and is the actively-researched compound. PPAP is historical only.

  • 30-50, executive maintenance
    SKIP-FOR-NOW

    Same logic. Selegiline or BPAP fill the slot more cleanly.

  • 50+, mild cognitive decline
    SKIP-FOR-NOW

    Selegiline has the actual evidence base in this demographic. PPAP would be experimentation without evidence support.

  • Anxiety-prone
    SKIP

    NE-elevating CAE compound with reported anxiety at higher doses + zero formal safety data is not the right fit.

  • High athletic load, tested status
    SKIP

    PPAP is structurally a phenethylamine derivative — could trigger urine amphetamine screen false positives. Not WADA-listed by name but the IOC's "and related substances" catch-all clause likely includes PPAP. Tested athletes should not touch this.

  • Sleep-disordered
    SKIP

    Adding any DA/NE enhancer with poor characterization is the wrong move when sleep is the limiting factor.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    No mechanism here is recovery-specific. BPC-157, GHK-Cu, methylene blue have stronger cases.

  • Strength/anabolic-focused
    SKIP

    Not in the anabolic pathway at all. Verdict across all archetypes: SKIP-FOR-NOW or WATCH-LIST at most. No archetype gets a STRONG-CANDIDATE or even OPTIONAL-ADD verdict for PPAP because BPAP exists and dominates on every dimension that matters.

▸ Subjective experience (deep)

Per the very limited research-chem user reports:

  • Onset: 30-60 min sublingual / oral
  • Peak: ~2-3 hours
  • Duration: ~5 hours total
  • Profile: "Amphetamine-like focus without tunnel vision," motivation lift, mental clarity, mild physical activation. Not euphoric. Less intense than amphetamine, less wired than methylphenidate. Some users describe it as "selegiline-like but with more drive."
  • Variability: Reports range from "noticeable" to "barely perceptible" — typical for low-potency CAE compounds where individual baseline DA tone strongly modulates response.
  • Honesty caveat: The user-experience corpus is so thin that subjective characterization is closer to vibes than data. Anyone considering PPAP would essentially be doing n=1 experimentation.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown in humans. Animal data (acute dosing studies) doesn't address chronic use. Mechanism prediction would be low tolerance (impulse-coupled release doesn't drive the supraphysiologic flooding that downregulates D2). But this is not validated.
  • Recommended cycle: No data. If using, default to weekday-on / weekend-off until data exists.
  • Reset protocol: Unknown. Days of washout, presumably.
▸ Stacking deep dive

Synergistic with (theoretical, no human evidence)

  • modafinil: Different mechanisms — modafinil raises orexin/histamine + weak DAT inhibition; PPAP enhances impulse-coupled DA/NE release + (per 2025 data) DAT inhibition. Limited research-chem reports describe additive focus. Caveat: the DAT-overlap means the "different mechanisms" framing is partly broken — both compounds touch DAT.
  • bromantane: Bromantane upregulates DA synthesis (substrate-side); PPAP enhances release per impulse (output-side). Mechanistically clean — synthesis + release work on different stages. No human stack data.

Avoid stacking with

  • selegiline: NEVER COMBINE. Both target the CAE/TAAR1 mechanism. Adding PPAP to selegiline (especially at any tier above 5 mg oral selegiline) produces overlapping CAE drive with no cleanly characterized human pharmacokinetic data on the combination. Pick one. If MAO-B inhibition is desired, use selegiline alone. If pure CAE without MAO inhibition is desired, use BPAP alone (not PPAP).
  • bpap: Same family, redundant. Pick one.
  • MAOIs (phenelzine, tranylcypromine, rasagiline, linezolid, methylene blue): Hypertensive crisis + serotonin syndrome risk. PPAP itself doesn't inhibit MAO, but raising synaptic catecholamines in the presence of MAO-A inhibition is the classic pressor-amine setup.
  • SSRIs / SNRIs: Theoretical serotonin syndrome risk via the catecholamine-serotonin crosstalk pathways. PPAP itself is catecholamine-selective (not serotonergic) so this risk is lower than with BPAP, but it is still nonzero.
  • Amphetamines / methylphenidate / cocaine: Additive DAT load (per 2025 reuptake data) + additive sympathomimetic activation. Avoid.
  • Tramadol, meperidine, methadone, DXM: Same serotonergic-opioid cautions as for any monoamine-active drug.

Neutral / safe co-administration (theoretical)

  • Caffeine: no known interaction.
  • Magnesium / D3 / K2 / DHA / NAC / citicoline: neutral.
  • Russian peptides (Semax, Selank, Adamax): no documented interaction.
▸ Drug interactions deep dive

PPAP has no validated CYP-enzyme interaction profile published. Its parent compound class (phenethylamines) typically interact with CYP2D6 / CYP2B6 — but PPAP-specific CYP characterization is absent. Absence of data ≠ absence of interaction; treat with caution.

▸ Pharmacogenomics

None published for PPAP specifically. By inference from the deprenyl/CAE family:

  • TAAR1 polymorphisms could plausibly modulate response (TAAR1 is the proposed mechanism target).
  • DRD2/ANKK1 Taq1A: D2 receptor density baseline. Plausibly affects response to any DA-enhancing compound including PPAP.
  • COMT Val158Met: Met/Met (high PFC DA tone) might respond less / get more anxiety; Val/Val (low PFC DA tone) might benefit more.

For Dylan's 23andMe results (June 2026): these SNPs are checked anyway for selegiline/bromantane/modafinil response — the same panel covers PPAP-relevant inference.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem powder (HCl) Venogen $39.95/g Medium-high (claims 99%, 3rd-party HPLC, COA available); often out of stock Worldwide shipping; explicitly "not for human use"
Research-chem powder Kimera Chems $77-92/g Medium (claims ≥98% HPLC, COA available as image on product page) Stocked; powder or DMSO/PEG400 liquid (20 mg/mL)
Research-chem powder Umbrella Labs Variable Medium Has stocked PPAP intermittently
Research-chem powder Euro-Nootropics Variable Low-medium Less established vendor
Research-chem powder GlobalChemSolutions Variable Low Less established
Bulk Alibaba Various Chinese suppliers ~$10/g at 50g+ scale Low (no COA, no quality assurance) Historical group-buy path; not recommended
Newmind Discontinued / unreliable — Low User reports of months-long stockouts circa 2018-2020

Cost reality: PPAP at 30 mg/dose × 30 days = 0.9 g/month. At Venogen pricing ($39.95/g) that's ~$36/month for ingredient. At Kimera ($77-92/g) that's ~$70-83/month. For comparison, BPAP at 1 mg/dose × 30 days = 0.03 g/month — at typical BPAP pricing of $40-60 per ~30 mg, that's ~$40-60/month for the ingredient. The two compounds end up at roughly similar monthly cost despite the 30-50× dose difference, because BPAP is priced higher per gram.

For Dylan: do not source. This is the kind of compound to recognize, understand its place in pharmacology history, and skip.

▸ Biomarkers to track (deep)

If somehow used (against this verdict):

  • Baseline: Resting BP, orthostatic BP, HR, mood self-report, sleep onset latency, liver panel.
  • During use: BP + HR weekly first month; sleep metrics; mood/drive self-report; watch for any hypertensive symptoms.
  • Post-cycle: BP + mood return to baseline within 1-2 weeks expected (no human data to confirm).
▸ Controversies / open debates Live debate

"Pure CAE" vs "DAT inhibitor" — the 2025 mechanism revision

Knoll's 1990s-2000s framing of PPAP was "pure impulse-coupled CAE, no reuptake inhibition, no direct release." The 2025 in-vitro reuptake data (PPAP DAT IC50 57.5 nM, more potent than amphetamine at DAT) directly contradicts the no-reuptake claim. My read: Knoll's assays (synaptosomal release in tissue prep) may have systematically missed reuptake inhibition. Or the mechanism is genuinely dual — CAE activity gated by impulse firing PLUS reuptake inhibition raising tonic levels. Either way, the original "pure physiological-gated DA enhancer" branding is now somewhat overstated. This matters because the "no abuse liability, no neurotoxicity, no tolerance" predictions all depend on the impulse-coupled-only story. If PPAP is also a potent DAT inhibitor, those predictions need re-derivation.

Why didn't PPAP reach human trials when Knoll wanted it to?

Knoll's group attempted clinical development. It didn't happen. The likely explanation is some combination of: (1) amphetamine derivative status creating regulatory friction in the post-MDMA crackdown era of the 1990s, (2) limited commercial interest in a "weaker amphetamine" compared to the booming SSRI-class antidepressant market, (3) Knoll himself moving on to BPAP almost immediately upon synthesis, leaving PPAP a dead-letter compound. There is no documented safety reason for the failure to reach trials.

BPAP supersession — is anything lost?

PPAP's distinguishing feature vs BPAP is catecholamine selectivity (no serotonin enhancement). For someone who specifically wants DA + NE enhancement without any serotonin elevation — e.g., someone on an SSRI who wants additive cognition without serotonin syndrome risk — PPAP would theoretically be safer than BPAP. Caveat: this theoretical edge has never been tested clinically. It's a hypothesis, not a documented advantage.

The TAAR1-agonism family hypothesis

2020s neurochem reviews group PPAP, BPAP, and selegiline as TAAR1 agonists (EPPTB-reversal evidence is strongest for BPAP). If true, the entire CAE family shares a single G-protein-coupled-receptor mechanism. This would make PPAP/BPAP/selegiline functionally equivalent at sufficient receptor occupancy — the differences (potency, selectivity, MAO inhibition vs not) would be secondary properties. PPAP-specific EPPTB-reversal data is thinner than for BPAP, leaving this an open question.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW HIGH confidence. PPAP is a historical compound superseded by BPAP on every relevant dimension. For Dylan-archetype, the CAE slot is filled by selegiline (Rx, evidence, daily-safe) or BPAP (research-chem, ~130× more potent than PPAP, also adds serotonin enhancement). PPAP would only be relevant if BPAP sourcing collapsed AND a serotonin-avoidance use case emerged — neither expected.
▸ Open questions / gaps Open
  1. Why no human trial in 30+ years? The historical record is sparse. Was a Phase 1 ever attempted? Why did it fail? Knowing this would clarify whether PPAP has an undisclosed safety problem or just lost the corporate-development race to BPAP.
  2. Pure-CAE vs DAT-inhibitor mechanism dominance. If PPAP is mostly a DAT inhibitor with secondary CAE, its safety/abuse profile predictions need revision. A cleanly designed in-vivo experiment (e.g., DAT-knockout mice + PPAP behavior) would settle this. None published as of 2026-05.
  3. PPAP-specific EPPTB-reversal experiments. Confirms or refutes TAAR1 as the PPAP mechanism, independently of BPAP data. None published.
  4. Long-term chronic dosing toxicology in primates. Never done. Anyone using PPAP chronically is functionally testing this in n=1.
  5. Stereoselectivity of pharmacology. (-)-PPAP is the active enantiomer per Knoll's work, but most research-chem product is sold as racemic or unspecified-enantiomer "PPAP HCl." Does (+)-PPAP have its own pharmacology? Unknown.
▸ Sources (full, with our context)

Primary literature (Knoll lab, the original CAE work)

Modern reviews + mechanism updates

Sourcing references (research-chem vendors)

Anecdotal user reports (research-chem community)

Cross-references in this wiki

  • See selegiline.md for the parent CAE compound with 40+ years of human data and Rx access — the rational alternative for Dylan-archetype if MAO-B inhibition is also wanted.
  • See bpap.md (TO-RESEARCH-QUEUE Wave C, HIGH PRIORITY) for the ~130× more potent successor — the rational alternative if pure CAE without MAO inhibition is wanted.
  • See bromantane.md for a different DA-enhancement mechanism (synthesis upregulation, not impulse-coupled release) that's already in Dylan's V5 plan.
  • See modafinil.md for the wakefulness primary that fills a different cognitive slot.
Back to compact view